SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-23-028927
Filing Date
2023-06-20
Accepted
2023-06-20 16:13:05
Documents
8
Effectiveness Date
2023-06-20

Document Format Files

Seq Description Document Type Size
1 S-8 june_2023_s-8_kalv.htm S-8 169993
2 EX-5.1 kalv-ex5_1.htm EX-5.1 21107
3 EX-23.1 kalv-ex23_1.htm EX-23.1 2975
4 EX-99.1 kalv-ex99_1.htm EX-99.1 954738
5 EX-FILING FEES kalv-exfiling_fees.htm EX-FILING FEES 28074
6 GRAPHIC img28983514_0.jpg GRAPHIC 32230
7 GRAPHIC img158624773_0.jpg GRAPHIC 3625
8 GRAPHIC img158624773_1.jpg GRAPHIC 3625
  Complete submission text file 0000950170-23-028927.txt   1233020
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: S-8 | Act: 33 | File No.: 333-272777 | Film No.: 231025192
SIC: 2834 Pharmaceutical Preparations